Herbal composition PHY906 and its use in chemotherapy

Patent metadata

Field	Value
Publication number	US-10646530-B2
Application number	US-201816049381-A
Country	US
Kind code	B2
Filing date	Jul 30, 2018
Priority date	Feb 15, 2007
Publication date	May 12, 2020
Grant date	May 12, 2020

Abstract

This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy.

First claim

We claim:

1. A method of treating cancer in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of:
i) an herbal preparation comprising Scutellaria, Glycyrrhiza, Ziziphus , and Paeonia ; and
ii) a chemotherapeutic formulation comprising sorafenib, wherein said cancer is hepatocellular cancer, colorectal cancer or pancreatic cancer.

2. The method according to claim 1 wherein said herbal preparation comprises Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba , and Paeonia lactiflora.

3. The method according to claim 1 wherein said cancer is hepatocellular cancer.

4. The method according to claim 2 wherein said cancer is hepatocellular cancer.

5. The method according to claim 1 wherein said cancer is colorectal cancer.

6. The method according to claim 2 wherein said cancer is colorectal cancer.

7. The method according to claim 1 wherein said cancer is pancreatic cancer.

8. The method according to claim 2 wherein said cancer is pancreatic cancer.

9. The method according to claim 1 , wherein the herbal preparation is administered via oral route and sorafenib is administered via oral route.

10. The method according to claim 2 , wherein the herbal preparation is administered via oral route and sorafenib is administered via oral route.

11. The method according to claim 1 , wherein the herbal preparation is administered before sorafenib is administered.

12. The method according to claim 2 , wherein the herbal preparation is administered before sorafenib is administered.

13. The method according to claim 1 , wherein the mammal is a human.

14. The method according to claim 2 , wherein the mammal is a human.

15. The method according to claim 3 , wherein the mammal is a human.

16. The method according to claim 4 , wherein the mammal is a human.

17. A method of inhibiting the growth of a tumor comprising administering to a mammal in need thereof:
i) an herbal preparation comprising Scutellaria, Glycyrrhiza, Ziziphus , and Paeonia ; and
ii) a chemotherapeutic formulation comprising sorafenib, wherein said tumor is a tumor of a gastrointestinal cancer.

18. The method according to claim 17 wherein said gastrointestinal cancer is hepatocellular cancer, colorectal cancer or pancreatic cancer.

19. The method according to claim 17 wherein said herbal preparation comprises Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba , and Paeonia lactiflora.

20. The method according to claim 18 wherein said cancer is hepatocellular cancer.

21. The method according to claim 19 wherein said cancer is hepatocellular cancer.

22. The method according to claim 18 wherein said cancer is colorectal cancer.

23. The method according to claim 19 wherein said cancer is colorectal cancer.

24. The method according to claim 18 wherein said cancer is pancreatic cancer.

25. The method according to claim 19 wherein said cancer is pancreatic cancer.

26. The method according to claim 18 , wherein the herbal preparation is administered via oral route and sorafenib is administered via oral route.

27. The method according to claim 19 , wherein the herbal preparation is administered via oral route and sorafenib is administered via oral route.

28. The method according to claim 18 , wherein the herbal preparation is administered before sorafenib is administered.

29. The method according to claim 19 , wherein the herbal preparation is administered before sorafenib is administered.

30. The method according to claim 18 , wherein the mammal is a human.

31. The method according to claim 19 , wherein the mammal is a human.

32. The method according to claim 20 , wherein the mammal is a human.

33. The method according to claim 21 , wherein the mammal is a human.

Assignees

• Univ Yale

Inventors

• Liu Shwu-Huey
• Jiang Zaoli
• Cheng Yung-Chi

Classifications

• A61K36/539

  Scutellaria (skullcap) · CPC title

• A61K31/4412

  having oxo groups directly attached to the heterocyclic ring · CPC title

• A61K36/65

  Paeoniaceae (Peony family), e.g. Chinese peony · CPC title

• A61K31/7068

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• A61K36/725 Primary

  Ziziphus, e.g. jujube · CPC title